The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
FDA approves Susvimo for diabetic macular edema
Tum Rakshak Kahu Ko Darna
Tum Rakshak Kahu Ko Darna
The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
